Company news

Innoviva, Inc. (NASDAQ:INVA) news

Innoviva, Inc. news releases on 6ix. Latest, Aug 12, 2026: Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO(R), ZEVTERA(R) and NUZOLVENCE(R)…

Innoviva, Inc. (NASDAQ:INVA) news

Press releases & updates

Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO(R), ZEVTERA(R) and NUZOLVENCE(R) Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark Report

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

U.S. FDA Approves NUZOLVENCE(R) (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference

Beacon Biosignals Raises $86M to Accelerate AI-Driven Insights into Brain Health

Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress

Antheia Appoints Eric d'Esparbes as Chief Financial Officer

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

Innoviva to Participate in Upcoming Investor Conferences

Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

Innoviva Reports First Quarter 2025 Financial Results, Highlights Recent Company Progress

Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Innoviva to Participate in the UBS Global Healthcare Conference

Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Innoviva to Participate in the BofA Securities Health Care Conference

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

Innoviva to Participate in the Cantor Global Healthcare Conference

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

Innoviva Appoints Stephen Basso as Chief Financial Officer

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference

Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use

Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases